InsidersTradesSigma
Track the Calithera Biosciences, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Calithera Biosciences, Inc. has published 31 insider filings. Market capitalisation: €487. The latest transaction was reported on 31 January 2023 (Cession). Among the most active insiders: Wong Stephanie. Every trade is free.
31
Insider Decl.
n/a
Thresholds
n/a
3 ops.
Buy Volume
n/a
2 ops.
Sell Volume
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 January 2023
Declarations31 total
120,161 shares@ €0.3541100.0% of flowCommon StockSEC:0000899243-23-003071:0
526 shares@ US$0.44610.1% of flowCommon StockSEC:0000899243-23-002610:0
217 shares@ US$0.44610.1% of flowCommon StockSEC:0000899243-23-002608:0
317 shares@ US$0.44610.5% of flowCommon StockSEC:0000899243-23-002609:0
79 shares@ US$0.44610.6% of flowCommon StockSEC:0000899243-23-002611:0
279 shares@ US$0.44610.5% of flowCommon StockSEC:0000899243-23-002612:0
666 shares@ US$0.491511.88% mcap5.7% of flowCommon StockSEC:0000899243-22-003134:0
5,586 shares@ €0.43449.3% of flowCommon StockSEC:0000899243-22-003138:0
4,794 shares@ €0.43448.2% of flowCommon StockSEC:0000899243-22-003139:0
4,794 shares@ €0.43448.2% of flowCommon StockSEC:0000899243-22-003135:0
18,077 shares@ €0.584341.8% of flowCommon StockSEC:0000899243-22-001301:0
18,077 shares@ €0.584340.7% of flowCommon StockSEC:0000899243-22-001298:0
18,077 shares@ €0.584341.8% of flowCommon StockSEC:0000899243-22-001299:0
3,855 shares@ €0.584344.3% of flowCommon StockSEC:0000899243-22-001300:0
30,000 shares@ €0.738650.0% of flowCommon StockSEC:0000899243-21-044426:0
200,000 shares@ €0.741250.0% of flowCommon StockSEC:0000899243-21-044150:0
Canonical exit: 8 Feb 2022 (T+90)
100,000 shares@ €0.730250.0% of flowCommon StockSEC:0000899243-21-044154:0
Canonical exit: 8 Feb 2022 (T+90)
100,000 shares@ €0.730250.0% of flowCommon StockSEC:0000899243-21-044145:0
Canonical exit: 8 Feb 2022 (T+90)
12,000 shares0Common StockSEC:0000899243-21-043684:0
12,000 shares0Common StockSEC:0000899243-21-043686:0
30,000 shares0Common StockSEC:0000899243-21-043687:0
30,000 shares0Common StockSEC:0000899243-21-043680:0
30,000 shares0Common StockSEC:0000899243-21-043688:0
12,000 shares0Common StockSEC:0000899243-21-043692:0
30,000 shares0Common StockSEC:0000899243-21-043693:0
25 of 31 declarations
关于 Calithera Biosciences, Inc.
Calithera Biosciences, Inc. 是一家总部位于美国的生物制药公司，曾在美国纳斯达克市场上市。该公司于 2010 年在旧金山/南旧金山生物技术生态系统中成立，其战略围绕旨在干预肿瘤代谢和肿瘤免疫学的靶向疗法。其科学论点侧重于阻断癌细胞的关键生存途径，同时可能增强免疫细胞活性，这是肿瘤药物开发中一个常见但竞争激烈的领域。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1496671/000095017023011047/cala-20221231.htm?utm_source=openai)) 从运营角度来看，Calithera 最好被描述为一家临床阶段生物技术公司，而非商业制药公司。其商业模式依赖于发现和推进针对代谢和免疫癌症靶点的小分子候选药物。这使得该公司处于肿瘤学的一个利基市场，科学差异化很重要，但执行风险很高，竞争对手众多：大型制药公司、资金更充足的生物技术同行以及平台驱动的开发商都在争夺相同的临床和合作机会。因此，该公司的市场地位从未是规模领导者；它是一家专业的、研究密集型开发商，其价值取决于临床数据、融资渠道和监管进展。（[linkedin.com](https://www.linkedin.com/company/calithera-biosciences?utm_source=openai)) 最近最重要的进展是 Calithera 实际上已停止作为持续经营实体运营。2023 年 1 月，董事会批准了一项全面清算和解散计划，公司宣布停止所有临床开发项目并裁员。此后不久，纳斯达克通知 Calithera，认为该公司是“公共空壳公司”，并暂停了普通股的交易，随后将其摘牌。对于投资者而言，这是决定性背景：CALA 不再是一个正常的运营生物技术股票故事，而是一个具有高度事件驱动经济学的清算案例证券。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1496671/000119312523014684/d181884d8k.htm?utm_source=openai)) 从国际股票分析的角度来看，该公司主要仍与历史参考、SEC 文件分析以及通过 Form 4 披露进行的内幕交易监控相关。因此，今天对 Calithera 的任何解读都应围绕剩余资产变现、解散机制和潜在分配结果，而不是产品收入或管线增长。简而言之，Calithera 是一家美国医疗保健公司，其投资案例已从肿瘤创新转向公司清盘和价值实现。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1496671/000119312523014684/d181884d8k.htm?utm_source=openai))
